### ü´Å Pulm/CC: Treatment of Severe Asthma with Tezepelumab

#### ‚úÖ True Statements
1. **Severe asthma** is characterized by frequent exacerbations that may require emergency department visits or hospitalizations.
2. Treatment of severe asthma includes **high-dose inhaled glucocorticoid‚Äìformoterol combination therapy**, **long-acting inhaled muscarinic antagonists**, and sometimes long-term oral glucocorticoid treatment.
3. Newer therapies for severe asthma include **biologic agents** directed against **IgE** (e.g., omalizumab) and **interleukins** (e.g., mepolizumab, reslizumab).
4. Choice among biologic therapies is guided by the **asthma phenotype**, determined by clinical characteristics and biomarkers such as IgE levels and blood eosinophil counts.
5. **Tezepelumab** is a humanized monoclonal antibody that blocks **thymic stromal lymphopoietin**, an epithelial cytokine.
6. Unlike other biologic treatments, **tezepelumab use is not limited to a specific asthma phenotype** and it improves asthma control and reduces exacerbations regardless of phenotype.
7. **Macrolide antibiotics** (e.g., azithromycin) do not have a role in the long-term treatment of asthma.
8. **Dupilumab** is most effective in patients with an absolute eosinophil count greater than 150/ŒºL (0.15 √ó 10^9/L) and an elevated fractional exhaled nitric oxide (FeNO) level.
9. **Omalizumab** is indicated for severe asthma with elevated IgE levels and sensitivity to multiple allergens.
10. **Key Point:** Patients with severe asthma that remains difficult to control despite optimal therapy should be considered for biologic therapy; **tezepelumab is unique among biologics because its use is not limited to a specific asthma phenotype**.

#### üí¨ Extra(s)
2. Long-term oral glucocorticoid treatment is used only when necessary due to side effects.
4. Phenotyping combines clinical features and biomarkers to determine biologic eligibility.
8. This patient‚Äôs low eosinophil count and low FeNO level make dupilumab a suboptimal choice.
9. This patient lacks elevated IgE or allergies, making omalizumab inappropriate.

#### üìö Reference
Corren J, Menzies-Gow A, Bimmel J, et al; PATHWAY and NAVIGATOR study investigators. Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies. *Immunotherapy*. 2023;15:1327-40. PMID: 37772607 doi:10.2217/imt-2023-0109

#### üè∑Ô∏è Tags
#Pulm/CC #Asthma #SevereAsthma #Tezepelumab #Biologics #AmbulatoryCare

#### üÜî Question ID
PMMCQ24048

#### üïí Last Updated
February 2025

---

#### üìñ Related Text
MKSAP: Pulmonary Medicine, Airways Disease, Asthma, Management of Chronic Asthma

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. The goals of longitudinal asthma management are to control chronic asthma symptoms, prevent exacerbations, and minimize risk for persistent airway obstruction.
2. Asthma management follows a **stepwise approach** involving assessment of severity, symptom control, and therapy modification.
3. The **2020 National Asthma Education and Prevention Program (NAEPP)** and **2024 Global Initiative for Asthma (GINA)** guidelines provide stepwise approaches to asthma management, with GINA emphasizing inhaled glucocorticoid‚Äìlong-acting Œ≤2-agonist (LABA) combinations even for rescue therapy.
4. Well-controlled asthma is defined by **daytime symptoms fewer than twice weekly** and **nighttime symptoms fewer than twice monthly** in the prior 4 weeks.
5. Comorbidities such as **gastroesophageal reflux disease**, **sinus disease**, **obstructive sleep apnea**, **vocal cord dysfunction/inducible laryngeal obstruction**, and **obesity** are common in asthma and should be actively managed.
6. All patients with asthma require **quick-relief medication**; inhaled glucocorticoids are the most effective controller medications.
7. Short-acting Œ≤2-agonists (SABAs) have rapid onset of action and relieve acute symptoms but are not recommended as sole agents.
8. GINA recommends **inhaled glucocorticoid‚Äìformoterol** for rescue therapy; NAEPP continues to recommend as-needed SABA.
9. Inhaled glucocorticoids reduce airway inflammation, mucosal edema, and mucus hypersecretion but can cause local and systemic side effects depending on dose.
10. Long-acting Œ≤2-agonists improve control when added to inhaled glucocorticoids but must not be used as monotherapy due to risk of asthma-related death.
11. Long-acting muscarinic antagonists (LAMAs), such as tiotropium, improve lung function and reduce exacerbations when added to inhaled glucocorticoid‚ÄìLABA therapy.
12. Biologic therapies for severe asthma target type 2 inflammation, including IgE and interleukin pathways; **tezepelumab is the newest biologic with broad indications not limited by phenotype**.
13. **Nonpharmacologic asthma management** includes allergen avoidance, reduced tobacco smoke exposure, healthy diet, exercise, and in select cases, bronchial thermoplasty.

#### üí¨ Extra(s)
2. Therapy adjustment includes both step-up and step-down approaches depending on control and side effects.
7. Albuterol is the most commonly used SABA in the United States.
9. Local side effects of inhaled glucocorticoids include oral candidiasis and dysphonia.
13. Bronchial thermoplasty is considered for patients with FEV1 >60% predicted and severe, poorly controlled asthma despite high-dose inhaled glucocorticoid‚ÄìLABA therapy.

#### üè∑Ô∏è Related Text Tags
#Pulm/CC #Asthma #ChronicAsthma #NAEPP #GINA #Biologics #StepwiseTherapy #AirwayManagement

---

#### üñºÔ∏è Supplemental Figure(s)
<!--Figure: National Asthma Education and Prevention Program Guidelines on Asthma Management-->
<figure>
  <img src="National Asthma Education and Prevention Program Guidelines on Asthma Management.svg" alt="National Asthma Education and Prevention Program Guidelines on Asthma Management">
  <figcaption>Figure: National Asthma Education and Prevention Program Guidelines on Asthma Management. Source: National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. NIH publication 20-HL-8140. Accessed January 8, 2025.</figcaption>
</figure>

#### üîä Supplemental Video(s)
<!-- None -->

#### üóæ Supplemental HTML Table(s)
<!--Table: GINA Guidelines for Starting Treatment in Adults and Adolescents with a Diagnosis of Asthma-->
<table>
  <caption><strong>GINA Guidelines for Starting Treatment in Adults and Adolescents with a Diagnosis of Asthma</strong></caption>
  <thead>
    <tr>
      <th rowspan="2">Track</th>
      <th colspan="5">Steps</th>
    </tr>
    <tr>
      <th>Step 1</th>
      <th>Step 2</th>
      <th>Step 3</th>
      <th>Step 4</th>
      <th>Step 5</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td rowspan="3">Track 1 (preferred controller and reliever)</td>
      <td>Symptoms &lt;4‚Äì5 d/wk</td>
      <td>Symptoms &lt;4‚Äì5 d/wk</td>
      <td>Symptoms most days or waking with asthma ‚â• once/wk</td>
      <td>Daily symptoms, or waking with asthma ‚â• once/wk, and low lung function</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td colspan="5"><em>Controller regimen:</em> Step 1‚Äì2: As-needed low-dose ICS‚Äìformoterol; Step 3: Low-dose maintenance ICS‚Äìformoterol; Step 4: Medium-dose maintenance ICS‚Äìformoterol; Step 5: Add on LAMA, assess phenotype, consider high-dose maintenance ICS‚Äìformoterol ¬± anti-IgE, anti‚ÄìIL-5/5R, anti‚ÄìIL-4RŒ±, anti-TSLP.</td>
    </tr>
    <tr>
      <td colspan="5"><em>Reliever:</em> As-needed low-dose ICS‚Äìformoterol.</td>
    </tr>
    <tr>
      <td rowspan="3">Track 2 (alternative controller and reliever)</td>
      <td>Symptoms &lt; twice/mo</td>
      <td>Symptoms ‚â• twice/mo but &lt;4‚Äì5 d/wk</td>
      <td>Symptoms most days or waking with asthma ‚â• once/wk</td>
      <td>Daily symptoms, or waking with asthma ‚â• once/wk, and low lung function</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td colspan="5"><em>Controller regimen:</em> Step 1: Take ICS whenever SABA taken; Step 2: Low-dose maintenance ICS; Step 3: Low-dose maintenance ICS‚ÄìLABA; Step 4: Medium/high-dose maintenance ICS‚ÄìLABA; Step 5: Add on LAMA, assess phenotype, consider high-dose maintenance ICS‚ÄìLABA ¬± anti-IgE, anti‚ÄìIL-5/5R, anti-IL-4RŒ±, anti-TSLP.</td>
    </tr>
    <tr>
      <td colspan="5"><em>Reliever:</em> As-needed ICS‚ÄìSABA or as-needed SABA.</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="6">
        Abbreviations: ICS = inhaled corticosteroid (glucocorticoid); LABA = long-acting Œ≤<sub>2</sub>-agonist; LAMA = long-acting muscarinic antagonist; SABA = short-acting Œ≤<sub>2</sub>-agonist; TSLP = thymic stromal lymphopoietin; IL = interleukin. Information from Global Initiative for Asthma (GINA), 2024. Accessed November 21, 2024.
      </td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements (from Table: *GINA Guidelines for Starting Treatment in Adults and Adolescents with a Diagnosis of Asthma*)
1. In **Track 1 (preferred)**, the reliever at all steps is **as-needed low-dose inhaled glucocorticoid‚Äìformoterol**.
2. In **Track 1**, controller therapy progresses from **as-needed low-dose inhaled glucocorticoid‚Äìformoterol** (Steps 1‚Äì2) to **low-dose** (Step 3) then **medium-dose maintenance inhaled glucocorticoid‚Äìformoterol** (Step 4).
3. At **Track 1 Step 5**, add a **long-acting muscarinic antagonist (LAMA)**, assess phenotype, and consider **high-dose inhaled glucocorticoid‚Äìformoterol** with or without biologics (**anti-IgE, anti‚ÄìIL-5/5R, anti‚ÄìIL-4RŒ±, anti-TSLP**).
4. In **Track 2 (alternative)**, **Step 1** uses **inhaled glucocorticoid whenever short-acting Œ≤2-agonist (SABA) is taken**.
5. In **Track 2**, controller therapy advances to **low-dose maintenance inhaled glucocorticoid‚ÄìLABA** at Step 3 and **medium/high-dose inhaled glucocorticoid‚ÄìLABA** at Step 4.
6. In **Track 2 Step 5**, add **LAMA**, assess phenotype, and consider **high-dose inhaled glucocorticoid‚ÄìLABA** with or without biologics (**anti-IgE, anti‚ÄìIL-5/5R, anti‚ÄìIL-4RŒ±, anti-TSLP**).
7. In **Track 2**, the reliever is **as-needed inhaled glucocorticoid‚ÄìSABA or as-needed SABA**.

#### üí¨ Optional Extra(s)
1. Track 1 symptoms thresholds by step (e.g., ‚Äúsymptoms most days or waking with asthma ‚â• once/wk‚Äù) guide progression of controller intensity.
4. Track 2 starts at lower symptom frequency (**< twice/month**) before escalating controller therapy by steps.

<!--Table: Comorbidities and Symptoms Associated With Asthma-->
<table>
  <caption><strong>Comorbidities and Symptoms Associated With Asthma</strong></caption>
  <thead>
    <tr>
      <th>Comorbidity</th>
      <th>Symptoms and Presentation</th>
      <th>Diagnosis and Treatment</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Gastroesophageal reflux disease (GERD)<sup>a</sup></td>
      <td>Frequently coexists with asthma; may independently cause respiratory symptoms (cough, chest pain)</td>
      <td>Empiric trial of a proton pump inhibitor for 2 months; consider endoscopy and 24-hour pH monitoring if symptoms do not improve</td>
    </tr>
    <tr>
      <td>Sinus disease<sup>b</sup></td>
      <td>Allergic rhinitis: rhinorrhea, nasal obstruction, itching, sneezing; may be seasonal, intermittent, or perennial. Chronic rhinosinusitis: facial pain, sinus pressure, sometimes anosmia.</td>
      <td>Intranasal glucocorticoids; for severe cases consider adding intranasal H<sub>1</sub>-antihistamines, oral antileukotrienes (if aspirin-exacerbated respiratory disease), oral glucocorticoids, immunotherapy, or biologics targeting IgE or eosinophils.</td>
    </tr>
    <tr>
      <td>Obstructive sleep apnea (OSA)<sup>c</sup></td>
      <td>Snoring, excessive daytime sleepiness, witnessed apneas; more common in patients with asthma; worsens asthma control and quality of life</td>
      <td>Confirm with polysomnography or home sleep testing; positive airway pressure improves asthma symptoms, quality of life, and peak flow rates</td>
    </tr>
    <tr>
      <td>Inducible laryngeal obstruction (ILO)</td>
      <td>Inspiratory breathlessness with throat tightness or voice dysfunction; paradoxical vocal cord adduction during inspiration; often triggered by exercise, fumes/irritants, or stress; may mimic or coexist with asthma</td>
      <td>Laryngoscopy during a symptomatic episode shows paradoxical adduction; treat with speech‚Äìbehavioral therapy, minimize triggers, and address contributors (e.g., GERD, postnasal drip)</td>
    </tr>
    <tr>
      <td>Obesity<sup>d</sup></td>
      <td>Dyspnea, wheezing; higher prevalence of asthma with poorer control than in normal BMI; may confound diagnosis due to overlapping dyspnea and exertional wheeze</td>
      <td>Measure BMI and document reversible airflow obstruction in all evaluations; weight loss improves asthma control and lung function; bariatric surgery outcomes improve with greater weight loss</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="3">
        <sup>a</sup>See Gastroesophageal Reflux Disease in Gastroenterology. <sup>b</sup>See Sinusitis in Interdisciplinary Medicine. <sup>c</sup>See Obstructive Sleep Apnea in Pulmonary Medicine. <sup>d</sup>See Obesity in Endocrinology and Metabolism.
      </td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements (from Table: *Comorbidities and Symptoms Associated With Asthma*)
1. **GERD** commonly coexists with asthma and may cause respiratory symptoms; an **empiric 2-month proton pump inhibitor trial** is recommended before further testing.
2. **Allergic rhinitis** and **chronic rhinosinusitis** are frequent in asthma; intranasal glucocorticoids are first-line, with add-on options for severe cases.
3. **Obstructive sleep apnea** is more common in asthma and worsens control; **positive airway pressure** improves asthma symptoms and peak flow.
4. **Inducible laryngeal obstruction** can mimic asthma and is diagnosed by **laryngoscopy during symptoms**; **speech‚Äìbehavioral therapy** and trigger minimization are recommended treatments.
5. **Obesity** is linked to poorer asthma control; **weight loss** improves control and lung function.

#### üí¨ Optional Extra(s)
1. If GERD symptoms persist after empiric therapy, consider **endoscopy** and **24-hour pH monitoring**.
3. OSA can be confirmed by **polysomnography** or **home sleep testing**.

<!--Table: Asthma Drug Formulations and Adverse Effects-->
<table>
  <caption><strong>Asthma Drug Formulations and Adverse Effects</strong></caption>
  <thead>
    <tr>
      <th>Drug/Class</th>
      <th>Formulations</th>
      <th>Adverse Effects</th>
    </tr>
  </thead>
  <tbody>
    <tr><td colspan="3"><strong>Short-Acting Œ≤<sub>2</sub>-Agonists</strong></td></tr>
    <tr><td>Albuterol</td><td>HFA-MDI, nebulizer solution</td><td>Tachycardia, hypokalemia</td></tr>
    <tr><td>Levalbuterol</td><td>HFA-MDI, nebulizer solution</td><td>Should not be used as monotherapy</td></tr>

    <tr><td colspan="3"><strong>Short-Acting Anticholinergics (Muscarinic Antagonists)</strong></td></tr>
    <tr><td>Ipratropium bromide</td><td>HFA-MDI, nebulizer solution</td><td>Dry mouth, tachycardia, rare acute narrow-angle glaucoma</td></tr>
    <tr><td>Albuterol/ipratropium bromide</td><td>HFA-MDI, nebulizer solution</td><td>Combined effects of both drug classes</td></tr>

    <tr><td colspan="3"><strong>Long-Acting Œ≤<sub>2</sub>-Agonists</strong></td></tr>
    <tr><td>Formoterol<sup>a</sup></td><td>DPI</td><td>Tremor, tachycardia; boxed warning against LABA monotherapy in asthma</td></tr>
    <tr><td>Salmeterol</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Arformoterol<sup>a</sup></td><td>Nebulizer solution</td><td>As above</td></tr>
    <tr><td>Formoterol fumarate<sup>a</sup></td><td>Nebulizer solution</td><td>As above</td></tr>
    <tr><td>Olodaterol<sup>a</sup></td><td>SMI</td><td>As above</td></tr>
    <tr><td>Indacaterol maleate<sup>a</sup></td><td>DPI</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Long-Acting Muscarinic Antagonists</strong></td></tr>
    <tr><td>Tiotropium</td><td>DPI, SMI</td><td>Dry mouth, urinary retention, rare acute narrow-angle glaucoma</td></tr>
    <tr><td>Aclidinium bromide</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Umeclidinium</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Glycopyrrolate</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Revefenacin</td><td>Nebulizer solution</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Inhaled Glucocorticoids</strong></td></tr>
    <tr><td>Beclomethasone</td><td>HFA-MDI</td><td>Dysphonia, xerostomia, oral candidiasis, bruising, pneumonia; low incidence of systemic adverse effects</td></tr>
    <tr><td>Budesonide</td><td>DPI, nebulizer solution</td><td>As above</td></tr>
    <tr><td>Fluticasone propionate</td><td>HFA, DPI</td><td>As above</td></tr>
    <tr><td>Fluticasone furoate</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Mometasone</td><td>DPI</td><td>As above</td></tr>
    <tr><td>Ciclesonide</td><td>HFA-MDI</td><td>As above</td></tr>
    <tr><td>Flunisolide</td><td>HFA-MDI</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Inhaled Glucocorticoid/LABA Combinations</strong></td></tr>
    <tr><td>Budesonide/formoterol<sup>a</sup></td><td>HFA</td><td>Combined adverse effects of both classes</td></tr>
    <tr><td>Fluticasone/salmeterol</td><td>HFA, DPI</td><td>As above</td></tr>
    <tr><td>Mometasone furoate/formoterol fumarate<sup>a</sup></td><td>HFA</td><td>As above</td></tr>
    <tr><td>Fluticasone furoate/vilanterol<sup>a</sup></td><td>DPI</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Oral Glucocorticoids</strong></td></tr>
    <tr><td>Prednisone</td><td>Tablet, liquid</td><td>Bruising, adrenal suppression, osteoporosis, glaucoma, diabetes mellitus, opportunistic infection, insomnia, cataracts, hypertension, weight gain, myopathy, acne</td></tr>
    <tr><td>Prednisolone</td><td>Tablet, liquid</td><td>As above</td></tr>
    <tr><td>Methylprednisolone</td><td>IV infusion, tablet</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Leukotriene-Modifying Agents</strong></td></tr>
    <tr><td>Montelukast</td><td>Tablet</td><td>Headache; rarely liver disease; neuropsychiatric events including suicidal thoughts/actions</td></tr>
    <tr><td>Zafirlukast</td><td>Tablet</td><td>As above</td></tr>
    <tr><td>Zileuton (5-lipoxygenase inhibitor)</td><td>Tablet</td><td>As above</td></tr>

    <tr><td colspan="3"><strong>Biologic Agents</strong></td></tr>
    <tr><td>Omalizumab (anti-IgE)</td><td>Subcutaneous injection</td><td>Anaphylaxis; increased risk for malignancy</td></tr>
    <tr><td>Mepolizumab (anti-IL-5)</td><td>Subcutaneous injection</td><td>Hypersensitivity reactions, headache, helminth infections</td></tr>
    <tr><td>Reslizumab (anti-IL-5)</td><td>IV infusion</td><td>Anaphylaxis, headache, helminth infections</td></tr>
    <tr><td>Benralizumab (anti-IL-5)</td><td>Subcutaneous injection</td><td>Hypersensitivity reactions, helminth infections</td></tr>
    <tr><td>Dupilumab (anti-IL-4/IL-13)</td><td>Subcutaneous injection</td><td>Hypersensitivity reactions, helminth infections</td></tr>
    <tr><td>Tezepelumab (anti-TSLP)</td><td>Subcutaneous injection</td><td>Hypersensitivity reactions</td></tr>

    <tr><td colspan="3"><strong>Other</strong></td></tr>
    <tr><td>Theophylline</td><td>Tablet, capsule, liquid</td><td>Tachycardia, nausea; overdose can be fatal</td></tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="3">
        Abbreviations: HFA = hydrofluoroalkane; MDI = metered-dose inhaler; DPI = dry powder inhaler; SMI = soft-mist inhaler; IL = interleukin; LABA = long-acting Œ≤<sub>2</sub>-agonist; TSLP = thymic stromal lymphopoietin. <sup>a</sup>Relief of acute bronchospasm is an off-label indication for some agents as noted.
      </td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements (from Table: *Asthma Drug Formulations and Adverse Effects*)
1. **Albuterol** is available as an HFA-MDI and nebulizer solution and can cause **tachycardia and hypokalemia**.
2. **Levalbuterol** should **not be used as monotherapy**.
3. **Ipratropium bromide** adverse effects include **dry mouth** and **tachycardia**; acute narrow-angle glaucoma is rare.
4. **Long-acting Œ≤2-agonists** must **not be used as monotherapy** in asthma (boxed warning).
5. **Tiotropium** is a long-acting muscarinic antagonist that can cause **dry mouth** and **urinary retention**.
6. **Inhaled glucocorticoids** commonly cause **dysphonia** and **oral candidiasis**; systemic adverse effects are uncommon at standard doses.
7. **Inhaled glucocorticoid/LABA combinations** carry the combined adverse effects of both drug classes.
8. **Oral glucocorticoids** have numerous systemic adverse effects, including **adrenal suppression**, **osteoporosis**, and **hyperglycemia**.
9. **Montelukast** is associated with **neuropsychiatric events**, including suicidal thoughts and actions (rare).
10. **Tezepelumab** is administered by **subcutaneous injection** with **hypersensitivity reactions** as a noted adverse effect.

#### üí¨ Optional Extra(s)
4. Boxed warnings for LABAs pertain to their use **without** another controller medication.
8. Minimize long-term oral glucocorticoid use due to cumulative toxicity.

<!--Table: Characteristics of Biologic Agents Indicated to Treat Severe Asthma-->
<table>
  <caption><strong>Characteristics of Biologic Agents Indicated to Treat Severe Asthma</strong></caption>
  <thead>
    <tr>
      <th>Biologic Agent</th>
      <th>Target</th>
      <th>Guidelines<sup>b</sup></th>
      <th>Formulation</th>
      <th>Home Use</th>
      <th>Adverse Effects</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Omalizumab</td>
      <td>IgE</td>
      <td>Severe asthma; IgE 30‚Äì700 U/mL (30‚Äì700 kU/L) and atopy</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Anaphylaxis; increased risk of malignancy</td>
    </tr>
    <tr>
      <td>Mepolizumab</td>
      <td>IL-5</td>
      <td>Severe asthma; absolute eosinophils &gt;150/ŒºL (0.15 √ó 10^9/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions; headache; helminth infections</td>
    </tr>
    <tr>
      <td>Reslizumab</td>
      <td>IL-5</td>
      <td>Severe asthma; absolute eosinophils &gt;400/ŒºL (0.4 √ó 10^9/L)</td>
      <td>Intravenous infusion</td>
      <td>No</td>
      <td>Anaphylaxis; headache; helminth infections</td>
    </tr>
    <tr>
      <td>Benralizumab</td>
      <td>IL-5</td>
      <td>Severe asthma; absolute eosinophils &gt;150/ŒºL (0.15 √ó 10^9/L)</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions; helminth infections</td>
    </tr>
    <tr>
      <td>Dupilumab</td>
      <td>IL-4, IL-13</td>
      <td>Moderate to severe asthma; absolute eosinophils &gt;150/ŒºL (0.15 √ó 10^9/L) or dependence on systemic glucocorticoids</td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions; helminth infections</td>
    </tr>
    <tr>
      <td>Tezepelumab</td>
      <td>TSLP</td>
      <td>Severe asthma; add-on therapy<sup>b</sup></td>
      <td>Subcutaneous injection</td>
      <td>Yes</td>
      <td>Hypersensitivity reactions</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="6">Abbreviations: IL = interleukin; TSLP = thymic stromal lymphopoietin. <sup>a</sup>Specialty referral recommended. <sup>b</sup>Patients with severe asthma not adequately controlled on standard therapy.</td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements (from Table: *Characteristics of Biologic Agents Indicated to Treat Severe Asthma*)
1. **Omalizumab** targets **IgE** and is indicated for severe asthma with **IgE 30‚Äì700 U/mL** and atopy.
2. **Mepolizumab** and **benralizumab** target **IL-5** and are indicated when **blood eosinophils >150/ŒºL**.
3. **Reslizumab** targets **IL-5**, requires **intravenous infusion**, and is indicated when **eosinophils >400/ŒºL**.
4. **Dupilumab** targets **IL-4/IL-13** and is indicated for moderate to severe asthma with **eosinophils >150/ŒºL** or steroid dependence.
5. **Tezepelumab** targets **TSLP** and is approved as **add-on therapy** for severe asthma, irrespective of phenotype.
6. Except for reslizumab, these biologics are administered by **subcutaneous injection** and can be used at **home**.

#### üí¨ Optional Extra(s)
1. Anaphylaxis is a potential adverse effect with several biologics and warrants observation after dosing where appropriate.
3. Home administration is **not** recommended for **reslizumab** because it is given by **IV infusion**.

<!--Table: National Asthma Education and Prevention Program (NAEPP) 2020 Focused Updates: Summary-->
<table>
  <caption><strong>National Asthma Education and Prevention Program (NAEPP) 2020 Focused Updates: Summary</strong></caption>
  <thead>
    <tr>
      <th>Population</th>
      <th>Core Recommendations</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Adults &amp; adolescents with mild persistent asthma</td>
      <td>Use a <strong>daily inhaled glucocorticoid</strong> with an as-needed <strong>short-acting Œ≤<sub>2</sub>-agonist (SABA)</strong>, or use both on an as-needed basis.</td>
    </tr>
    <tr>
      <td>Adults &amp; adolescents with moderate persistent asthma</td>
      <td>Use <strong>single maintenance and reliever therapy (SMART)</strong> with a single inhaler containing <strong>inhaled glucocorticoid plus formoterol</strong> taken daily and as needed.</td>
    </tr>
    <tr>
      <td>Step-up therapy</td>
      <td>Use <strong>daily medium- to high-dose inhaled glucocorticoid plus LABA</strong>, add <strong>LAMA</strong>, and <strong>SABA as needed</strong>.</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="2">Source: National Heart, Lung, and Blood Institute. 2020 Focused Updates to the Asthma Management Guidelines (NIH 20-HL-8140). Accessed January 8, 2025.</td>
    </tr>
  </tfoot>
</table>

#### ‚úÖ True Statements (from Table: *NAEPP 2020 Focused Updates: Summary*)
1. For **mild persistent asthma**, NAEPP recommends **daily inhaled glucocorticoid** with as-needed SABA or using both as needed.
2. For **moderate persistent asthma**, NAEPP recommends **SMART** with **inhaled glucocorticoid‚Äìformoterol** as both maintenance and reliever.
3. **Step-up therapy** adds **LAMA** to **medium-/high-dose inhaled glucocorticoid‚ÄìLABA**, with **SABA** as needed.

#### üí¨ Optional Extra(s)
2. SMART uses **formoterol** because of its rapid onset suitable for reliever therapy.
